

SUPPLEMENTARY TABLE S3. DIFFERENTIATED THYROID CANCER AND THYROPEROXIDASE ANTIBODY STATUS

	<i>Non-DTC n (%)</i>	<i>DTC n (%)</i>	<i>Total n (%)</i>	<i>Relative risk (95% CI)</i>
Non-HT	1482 (84)	288 (16)	1770 (100)	—
Euth-HT TPO-High	31 (62)	19 (38)	50 (100)	1.04 (1.01–1.08) ^a
Euth-HT TPO-Low/Neg	52 (63)	30 (37)	82 (100)	1.07 (1.03–1.11) ^a
Hypo-HT LT ₄ -Low TPO-High	14 (64)	8 (36)	22 (100)	1.02 (1.00–1.04) ^b
LT ₄ -Low TPO-Low/Neg	1 (13)	7 (87)	8 (100)	1.02 (1.01–1.04) ^a
LT ₄ -Mid TPO-High	15 (94)	1 (60)	16 (100)	0.99 (0.99–1.00)
LT ₄ -Mid TPO-Low/Neg	6 (60)	4 (40)	10 (100)	1.00 (1.00–1.02)
LT ₄ -High TPO-High	18 (957)	1 (5)	19 (100)	0.99 (0.98–1.00)
LT ₄ -High TPO-Low/Neg	7 (70)	3 (30)	10 (100)	1.01 (0.99–1.02)

Relative risk is calculated compared to the Non-HT group by Fisher's exact test.

^aFisher's exact test $p < 0.001$.

^bFisher's exact test $p < 0.05$.

TPO, thyroid peroxidase antibodies; TPO-High, TPO antibodies titer > 1:1000; TPO-Low/Neg, TPO antibodies titer < 1:1000 or undetectable (negative); Non-HT, subjects without Hashimoto's thyroiditis; Euth-HT, euthyroid patients with Hashimoto's thyroiditis; Hypo-HT, hypothyroid patients with Hashimoto's thyroiditis; LT₄, hypothyroid patients on levothyroxine replacement; Low/Mid/High, tertiles of levothyroxine replacement dose; DTC, differentiated thyroid cancer (see text for details); CI, confidence interval.